Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
揭開爵士製藥的神祕面紗：來自15條分析師評論的見解
In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有15位分析師發佈了Jazz Pharmicals（納斯達克股票代碼：JAZZ）的評級，提出了從看漲到看跌的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $195.73, a high estimate of $230.00, and a low estimate of $131.00. Marking an increase of 1.35%, the current average surpasses the previous average price target of $193.12.
分析師通過對12個月目標股價的評估提供了更深入的見解，顯示平均目標價爲195.73美元，最高估計爲230.00美元，低估值爲131.00美元。當前的平均價格上漲了1.35％，超過了之前的平均目標股價193.12美元。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細明細
A clear picture of Jazz...
通過對分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。